A case report from researchers at the University of Colorado Anschutz Medical Campus in Aurora links tirzepatide, sold as Zepbound, to lithium toxicity in a 50-year-old woman with bipolar disorder. It is the fourth reported case of tirzepatide-associated lithium toxicity, MedPage Today reported Oct. 26. Jay Davis, MD, and colleagues published the case in the Journal of Clinical Psychopharmacology. Lithium remains a cornerstone of bipolar disorder treatment despite its limitations, the researchers said. The patient’s serum lithium level was 0.7 mmol/L before she started weekly 2.5-milligram tirzepatide injections for weight… Originally published in Becker’s Hospital Review. Read More
GLP-1 drugs may interact with a common psychiatric medication
Integrated Psychiatric Consultants
Office Hours:Mon-Fri, 9 a.m. - 5 p.m. CT